DRG Epidemiology’s coverage of osteoarthritis (OA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OA in each country, as…
DRG Epidemiology’s coverage of osteoarthritis (OA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OA in each country, as…
DRG Epidemiology’s coverage of osteoarthritis (OA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OA in each country, as…
DRG Epidemiology’s coverage of osteoarthritis (OA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OA in each country, as…
DRG Epidemiology’s coverage of osteoarthritis (OA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OA in each country, as…
Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the second half of…
The coronavirus disease 2019 (COVID-19) Epidemiology Forecaster is a fully customizable SEIR(susceptible, exposed, infectious, recovered) model that allows users to develop scenario-based global…
The number of total prevalent cases of MCI across the Asia-Pacific countries under study will increase by 55%, from 11 million in 2020 to 17 million in 2030. Among the countries considered…
Our forecasts are made on the basis of changing levels of exposure to known risk or protective factors rather than extrapolation of historical trends. Factors are included in our forecast model…
Our forecasts are made on the basis of changing levels of exposure to known risk or protective factors rather than extrapolation of historical trends. Factors are included in our forecast model…
The number of total prevalent cases of MCI across the countries under study will increase by 39%, from 2.8 million in to 3.9 million in 10 years. Among the countries considered in this…
The number of total prevalent cases of MCI across the countries under study will increase by 43%, from 58 million in 2020 to 83 million in 2030. Among the countries considered in this…
DRG Epidemiology’s coverage of malignant melanoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…